Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.42 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL871366 | 0.86 | LTA4H (0.54) | HRH3KDM4ELTA4HALDH1A1PSMB1 | |
| SCHEMBL585479 | 0.85 | PSMB1 (0.55) | HRH3KDM4ELTA4HPSMB1PSMB5 | |
| SCHEMBL24364468 | 0.84 | KDM4E (0.55) | HRH3KDM4ELTA4HALDH1A1SMN1; SMN2 | |
| SCHEMBL4089555 | 0.82 | LTA4H (0.46) | HRH3MAOBKDM4ELTA4H | |
| SCHEMBL4169739 | 0.82 | LTA4H (0.46) | HRH3MAOBKDM4ELTA4H | |
| SCHEMBL18824777 | 0.80 | HRH3 (0.56) | HRH3 | |
| SCHEMBL4094975 | 0.79 | HRH3 (0.46) | HRH3MAOBKDM4ELTA4H | |
| SCHEMBL237631 | 0.79 | HRH3 (0.58) | HRH3 | |
| SCHEMBL8443537 | 0.79 | KDM4E (0.57) | HRH3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5780789 | 0.79 | LPL (0.49) | KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | HRH3 2504/4885MAOB 3587/4885KDM4E 3468/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | HRH3 2769/4885MAOB 3738/4885KDM4E 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.